Paclitaxel (P) and cisplatin (C) concurrent with radiotherapy (RT) for larynx preservation (LP) in advanced resectable laryngeal (L) and hypopharyngeal (HP) squamous cell carcinoma (SCC): Final results of a prospective phase II trial.

Ulisses Ribaldo Nicolau,Thiago Bueno Oliveira,André Lopes Carvalho,Rosane Oliveira Sant'Ana,Adriana Domingues Valadares,João Victor Salvajoli,Ludmilla T.D. Chinen,Bertha Catherine B. Araujo,Sandro José Martins,Dalvaro Oliveira Castro Junior,Luiz Paulo Kowalski,Olavo Feher

Paclitaxel (P) and cisplatin (C) concurrent with radiotherapy (RT) for larynx preservation (LP) in advanced resectable laryngeal (L) and hypopharyngeal (HP) squamous cell carcinoma (SCC): Final results of a prospective phase II trial.

2017

Ulisses Ribaldo Nicolau
Thiago Bueno Oliveira
André Lopes Carvalho
Rosane Oliveira Sant'Ana
Adriana Domingues Valadares
João Victor Salvajoli
Ludmilla T.D. Chinen
Bertha Catherine B. Araujo
Sandro José Martins
Dalvaro Oliveira Castro Junior
Luiz Paulo Kowalski
Olavo Feher

e16046 Background: Since the results of the RTOG 9111 trial, cisplatin based chemoradiation (CRT) has been the standard of care for LP in advanced laryngeal SCC. Recently, the role of taxanes in ma...

Keywords:

Radiation therapy
Oncology
Internal medicine
Cell
Cisplatin
Larynx
Carcinoma
Pathology
Paclitaxel
Medicine
larynx preservation
basal cell
standard of care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations